Azacitidine

...at Pharmion (acquired by Celgene), Ms. Shoemaker was responsible for creating the commercial organization and the successful launch of Vidaza®, a chemotherapeutic agent for treating myelodysplastic syndrome and some types of leukemia. She...

In this article: Europe, FDA, United States, Genentech, Celgene, SEC, Novartis, and EU

...Syndromes (MDS). The FDA approved Vidaza, the first in a new class of drugs called demethylation agents, for treatment of all five MDS subtypes, which include both low-risk and high-risk patients. These subtypes include:...

In this article: Thrombocytopenia, FDA, Cancer, Leukopenia, Erythema, Antineoplastic, Leukemia, and Chest pain

...with higher-risk MDS. Azacitidine was also the first drug approved by the FDA for the treatment of all five French, American, British (FAB) MDS subtypes which includes both low-risk and high-risk patients. These subtypes include:...

In this article: Cancer, Thrombocytopenia, European Union, FDA, Celgene Corporation, CCR, and Acute myeloid leukemia

In August, Boulder, Colorado-based Pharmion said a late-stage trial of its drug Vidaza significantly extended the life of patients with myelodysplastic syndromes, a group of blood disorders that can lead to leukemia. Its shares...

In this article: Celgene Corp, Vidaza, Revlimid, Multiple myeloma, Market capitalization, Revenue, Leukemia, Dexamethasone, and Cancer

...the positive opinion from the European Union's Committee for Medicinal Products for Human Use (CHMP) recommending approval of VIDAZA (azacitidine) for specific types of MDS patients, including those with high-risk MDS, chronic...

In this article: Acute myeloid leukemia, CCR, Leukemia, Neoplasm, National Institute of Health, and European Union

...that often precede leukemia. "The Dacogen failure is a material positive for Celgene, as Vidaza is now likely to take a commanding share of the MDS market," J.P. Morgan analyst Geoffrey Meacham said in a note. "Commercially, it will be...

In this article: Dacogen, Celgene Corp, Vidaza, Johnson & Johnson, and Revenue

...lives , , ) said early Tuesday that a Phase III clinical study for its blood cancer drug Vidaza showed that patients using the product lived a little over 24 months, compared to 15 months for patients given standard treatments. Vidaza is...

In this article: Vidaza, Leukemia, Cancer, and U.S.

...myelomonocytic leukemia (CMMoL). Vidaza is believed to exert its antineoplastic effects by causing hypomethylation of DNA and direct cytotoxicity on abnormal hematopoietic cells in the bone marrow. The concentration of Vidaza required...

In this article: EU, Thrombocytopenia, Myelodysplastic, Acute myeloid leukemia, FDA, Leukopenia, and Erythema